Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy Study of IV Artesunate to Treat Malaria

This study has been completed.
Military Infectious Diseases Research Program (MIDRP)
Information provided by (Responsible Party):
U.S. Army Medical Research and Materiel Command Identifier:
First received: March 1, 2006
Last updated: February 1, 2017
Last verified: November 2016
The purpose of this study is to determine how GMP IV Artesunate is metabolized and cleared by individuals with uncomplicated malaria infection and to determine how fast it eliminates malaria infection from the body.

Condition Intervention Phase
Drug: Artesunate and Malarone
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase II, Open Label, Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of Intravenous Artesunate in Adults With Uncomplicated Malaria

Resource links provided by NLM:

Further study details as provided by U.S. Army Medical Research and Materiel Command:

Primary Outcome Measures:
  • Change in Percentage of Parasites Detected at 48 Hours [ Time Frame: 48 hours ]
    Change in Percentage of Parasites Detected at 48 Hours. With positive numbers to represent increases and negative numbers to represent decreases

Secondary Outcome Measures:
  • Percentage of Parasite Clearance [ Time Frame: 24 and 48 hours post dose ]
    The target variable is detection (percentage) of asexual stage parasites of Plasmodium falciparum malaria in bloodstream by Giemsa - stained microscopy of thick and thin blood smears

  • Number of Subjects With Fever Clearance [ Time Frame: Within 48 hours post dose ]
    Temperature is measured by oral digital thermometers, and fever clearance time is defined as the first time with resolution of fever (<37.5C) sustained for 24 hours

  • Safety - Severity of Adverse Events [ Time Frame: up to 14 days ]
    Determine the safety (defined as severity of AE's using the Common Toxicity Criteria)

  • Safety - Adverse Events Relationship to Study Drug [ Time Frame: up to 14 days ]
    Determine the safety (defined as relationship to study drug of AE's and SAE's)

  • Safety - Severity of Serious Adverse Events (SAE's) [ Time Frame: up to 14 days ]
    Determine the safety (defined as severity of SAE's using the Common Toxicity Criteria)

  • Safety - Serious Adverse Event (SAE) Relationship to Study Drug [ Time Frame: Up to 14 days ]
    Determine the safety (defined as relationship to study drug of SAE's)

Enrollment: 30
Study Start Date: March 2006
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Artesunate and Malarone
Subject are given intravenous Artesunate once a day for 3 days. Following completion of Artesunate treatment, all subjects received Malarone follow-on therapy to ensure parasitologic cure.
Drug: Artesunate and Malarone
Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)

Detailed Description:
This is an unblinded non-randomized phase II pharmacokinetic study of a new GMP formulation of intravenous artesunate. Artesunate has been used throughout Asia and Africa for many years. Its overall efficacy associated with the ability to lower parasitemia is well established. To date, pharmacokinetic studies have not been done in Africa using GMP (Good Manufacturing Practices)-produced drug. The objective of this study is to show that GMP IV artesunate rapidly clears parasites in Adult Kenyan populations with malaria and that the pharmacokinetic profile of the drug approximates other populations of adults tested (Asians and North Americans).

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult male & non-pregnant females, 18-65 years
  • Fever, defined as >37.5ºC, during the current illness, or history (within the last 48 hours) of fever.
  • Diagnosis of falciparum malaria, greater than or equal to 200 parasites/uL
  • Able to communicate well with the investigator and to comply with the requirements of the entire study.
  • Willing to be admitted for the period of drug administration and/or to follow up (return to hospital)
  • Provision of the written informed consent to participate as shown by a signature on the informed consent form.

Exclusion Criteria:

  • Administration of any investigational drug in the period 0 to 16 weeks before entry to the study.
  • The use of any medication during the period 0 to 14 days (prescribed drugs) or 0 to 5 days (OTC) before entry to the study (including herbal or dietary supplements), except those deemed by the principal investigator / clinical investigator not to interfere with the outcome of the study.
  • Existence of any surgical or medical condition that, in the judgment of the clinical investigator, might interfere with the distribution, metabolism or excretion of the drug.
  • History of serious adverse reaction or hypersensitivity to study drug or follow on treatment.
  • Mixed malaria infection (malaria other than falciparum malaria mono-infection as detected by screening blood smear)
  • Severe falciparum malaria (as defined by the WHO; Attachment 1).
  • Donation or loss of greater than 400 ml of blood in the period 0 to 12 weeks before entry to the study,
  • Transfusion of blood within past 30 days.
  • Refusal to prevent pregnancy during the 14 days of the trial
  • Pregnancy as defined clinically or by a positive urine BHCG at the time of screening, or nursing mothers.
  • Laboratory evidence or history of significant cardiovascular, liver or renal functional abnormality, which in the opinion of the investigator would place them at increased risk. Specifically, the following will serve as exclusionary lab values:

    • Creatinine >1.4 x ULN (>2.0 mg/dL)
    • Glucose <LLN (65mg/dL)
    • AST, ALT >3x ULN (120 U/L)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00298610

New Nyanza Provincial Hospital
Kisumu, New Nyanza, Kenya
Sponsors and Collaborators
U.S. Army Medical Research and Materiel Command
Military Infectious Diseases Research Program (MIDRP)
Principal Investigator: Shon A Remich, MD Walter Reed Army Institute of Research (WRAIR)
  More Information

Responsible Party: U.S. Army Medical Research and Materiel Command Identifier: NCT00298610     History of Changes
Other Study ID Numbers: WRAIR 1168
KEMRI 917 ( Other Identifier: IRB )
HSRRB A-13331 ( Other Identifier: IRB )
Study First Received: March 1, 2006
Results First Received: November 30, 2016
Last Updated: February 1, 2017
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by U.S. Army Medical Research and Materiel Command:
Uncomplicated Malaria
GMP artesunate

Additional relevant MeSH terms:
Protozoan Infections
Parasitic Diseases
Atovaquone, proguanil drug combination
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antimalarials processed this record on April 28, 2017